ERBB2 and cancer: A phase I trial (NCT02780401) evaluating the side effects and optimal dosing of pUMVC3-IGFBP2-HER2-IGF1R combined with Sargramostim in patients with nonmetastatic, node-positive, HER2-negative breast cancer aimed at preventing cancer recurrence [126].